// ============================================================
// LIVE DATA — Pulled from ClinicalTrials.gov API on Feb 10, 2026
// Real actively recruiting/active Phase 2-3 trials
// ============================================================

import type { TrialBiomarkerUsage, NewsUpdate } from '../types';

export const LIVE_TRIALS: TrialBiomarkerUsage[] = [
  // ===== NSCLC — PD-L1 =====
  { nctId: 'NCT06170788', trialTitle: 'TroFuse-007: Sac-TMT + Pembro vs Pembro in PD-L1 TPS≥50% NSCLC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: '50', cutoffUnit: '% TPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Merck', status: 'Recruiting', startYear: 2023 },
  { nctId: 'NCT06757401', trialTitle: 'BE6A LUNG-02: Sigvotatug Vedotin + Pembro vs Pembro PD-L1≥50% NSCLC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: '50', cutoffUnit: '% TPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Pfizer', status: 'Recruiting', startYear: 2025 },
  { nctId: 'NCT06767514', trialTitle: 'Ivonescimab vs Pembro in PD-L1 High mNSCLC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: '50', cutoffUnit: '% TPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Summit Therapeutics', status: 'Recruiting', startYear: 2025 },
  { nctId: 'NCT06984588', trialTitle: 'Uliledlimab+Toripalimab vs Pembro in PD-L1+/CD73+ NSCLC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 2/3', cutoffValue: '1', cutoffUnit: '% (PD-L1+CD73)', cutoffOperator: '>=', assayName: 'Dual biomarker IHC', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'TJ Biopharma', status: 'Active', startYear: 2024 },
  { nctId: 'NCT06008093', trialTitle: 'TRITON: Durva+Treme vs Pembro+Chemo in STK11/KEAP1/KRAS NSCLC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'STK11/KEAP1/KRAS', cutoffUnit: 'co-mutation', cutoffOperator: 'positive', assayName: 'NGS panel', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'AstraZeneca', status: 'Recruiting', startYear: 2024 },
  { nctId: 'NCT06712316', trialTitle: 'BNT327+Chemo vs Pembro+Chemo in 1L NSCLC (Ph2/3)', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 2/3', cutoffValue: '1', cutoffUnit: '% TPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'BioNTech', status: 'Recruiting', startYear: 2025 },
  { nctId: 'NCT04093167', trialTitle: 'ctDNA Response-Adaptive Immuno-Chemo in NSCLC (Ph2/3)', biomarkerName: 'ctDNA', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 2/3', cutoffValue: 'ctDNA response', cutoffUnit: 'detection', cutoffOperator: 'positive', assayName: 'ctDNA panel', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'CCTG', status: 'Recruiting', startYear: 2020 },
  { nctId: 'NCT03851445', trialTitle: 'LUNG-MAP: Biomarker-Driven Therapies & IO in Pre-Treated NSCLC', biomarkerName: 'TMB', setting: '2L', tumorType: 'NSCLC', phase: 'Phase 2/3', cutoffValue: '10', cutoffUnit: 'mut/Mb', cutoffOperator: '>=', assayName: 'FoundationOne CDx', assayManufacturer: 'Foundation Medicine', companionDiagnostic: true, sponsor: 'SWOG/NCI', status: 'Recruiting', startYear: 2019 },

  // ===== NSCLC — KRAS =====
  { nctId: 'NCT06345729', trialTitle: 'KANDLELIT-004: MK-1084+Pembro vs Pembro KRAS G12C PD-L1≥50% NSCLC', biomarkerName: 'KRAS', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'G12C + PD-L1≥50%', cutoffUnit: 'dual biomarker', cutoffOperator: 'positive', assayName: 'NGS + 22C3', assayManufacturer: 'Various + Dako', companionDiagnostic: true, sponsor: 'Merck', status: 'Recruiting', startYear: 2024 },

  // ===== NSCLC — EGFR =====
  { nctId: 'NCT04302025', trialTitle: 'NAUTIKA1: Biomarker-Selected Neoadjuvant Therapy Resectable NSCLC', biomarkerName: 'EGFR', setting: 'Neoadjuvant', tumorType: 'NSCLC', phase: 'Phase 2', cutoffValue: 'EGFR/ALK/RET/BRAF/NTRK', cutoffUnit: 'actionable mutation', cutoffOperator: 'positive', assayName: 'FoundationOne CDx', assayManufacturer: 'Foundation Medicine', companionDiagnostic: true, sponsor: 'Genentech/Roche', status: 'Recruiting', startYear: 2020 },

  // ===== NSCLC — HER2 =====
  { nctId: 'NCT06899126', trialTitle: 'DESTINY-Lung06: T-DXd+Pembro vs Chemo+Pembro HER2+ nsNSCLC', biomarkerName: 'HER2', setting: '1L', tumorType: 'NSCLC', phase: 'Phase 3', cutoffValue: 'HER2 overexpressing', cutoffUnit: 'IHC 2+/3+', cutoffOperator: '>=', assayName: 'HercepTest', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Daiichi Sankyo', status: 'Recruiting', startYear: 2025 },

  // ===== BREAST CANCER — PD-L1 =====
  { nctId: 'NCT05382286', trialTitle: 'SG+Pembro vs TPC+Pembro in PD-L1+ 1L mTNBC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'Breast Cancer', phase: 'Phase 3', cutoffValue: '10', cutoffUnit: 'CPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Gilead Sciences', status: 'Active', startYear: 2022 },
  { nctId: 'NCT05382299', trialTitle: 'SG vs TPC in PD-L1 Negative 1L mTNBC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'Breast Cancer', phase: 'Phase 3', cutoffValue: '0', cutoffUnit: 'CPS (negative)', cutoffOperator: '<', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Gilead Sciences', status: 'Active', startYear: 2022 },
  { nctId: 'NCT03725059', trialTitle: 'KEYNOTE-756: Pembro+NeoAdj Chemo in HR+/HER2- High-Risk BC', biomarkerName: 'PD-L1', setting: 'Neoadjuvant', tumorType: 'Breast Cancer', phase: 'Phase 3', cutoffValue: 'CPS assessed', cutoffUnit: 'CPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: false, sponsor: 'Merck', status: 'Active', startYear: 2018 },

  // ===== BREAST CANCER — HER2-LOW/ULTRALOW =====
  { nctId: 'NCT05945732', trialTitle: 'DESTINY-Breast Respond: T-DXd RWD in HER2-low mBC (Europe)', biomarkerName: 'HER2', setting: '2L', tumorType: 'Breast Cancer', phase: 'Observational', cutoffValue: 'HER2-low (1+, 2+/ISH-)', cutoffUnit: 'IHC', cutoffOperator: '>=', assayName: 'Local HER2 IHC/ISH', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'Daiichi Sankyo', status: 'Recruiting', startYear: 2023 },
  { nctId: 'NCT07198724', trialTitle: 'ERADICATE: Elacestrant+T-DXd in HR+/HER2-low/ultralow mBC', biomarkerName: 'HER2', setting: '3L+', tumorType: 'Breast Cancer', phase: 'Phase 1/2', cutoffValue: 'HER2-low/ultralow', cutoffUnit: 'IHC (includes 0 faint)', cutoffOperator: '>=', assayName: 'Quantitative HER2 IHC', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'Academic', status: 'Recruiting', startYear: 2026 },
  { nctId: 'NCT05633979', trialTitle: 'Valemetostat+T-DXd in HER2 Low/Ultra-low/Null mBC', biomarkerName: 'HER2', setting: '3L+', tumorType: 'Breast Cancer', phase: 'Phase 1b', cutoffValue: 'HER2-low/ultralow/null', cutoffUnit: 'IHC full spectrum', cutoffOperator: '>=', assayName: 'Quantitative HER2 IHC', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'MD Anderson', status: 'Active', startYear: 2023 },

  // ===== BREAST CANCER — BRCA =====
  { nctId: 'NCT05708235', trialTitle: 'ctDNA MRD in HR+/HER2- Early BC on CDK4/6i', biomarkerName: 'ctDNA', setting: 'Adjuvant', tumorType: 'Breast Cancer', phase: 'Phase 2', cutoffValue: 'Persistent ctDNA', cutoffUnit: 'detection', cutoffOperator: 'positive', assayName: 'ctDNA panel', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'MedSIR', status: 'Recruiting', startYear: 2024 },

  // ===== COLORECTAL CANCER — MSI =====
  { nctId: 'NCT05482516', trialTitle: 'ctDNA MRD-Guided Atezo+Bev in Curatively Treated GI Cancers', biomarkerName: 'ctDNA', setting: 'Adjuvant', tumorType: 'Colorectal Cancer', phase: 'Phase 3', cutoffValue: 'ctDNA MRD+', cutoffUnit: 'detection', cutoffOperator: 'positive', assayName: 'Signatera', assayManufacturer: 'Natera', companionDiagnostic: false, sponsor: 'Georgetown University', status: 'Recruiting', startYear: 2023 },
  { nctId: 'NCT05534087', trialTitle: 'MRD-Guided Treatment Intensification Stage II-III Colon Cancer', biomarkerName: 'ctDNA', setting: 'Adjuvant', tumorType: 'Colorectal Cancer', phase: 'Phase 3', cutoffValue: 'ctDNA positive (MRD+)', cutoffUnit: 'detection', cutoffOperator: 'positive', assayName: 'Signatera', assayManufacturer: 'Natera', companionDiagnostic: false, sponsor: 'Seoul Natl University', status: 'Recruiting', startYear: 2022 },

  // ===== MELANOMA =====
  { nctId: 'NCT06070012', trialTitle: 'TARGET-tebe: Tebentafusp in HLA-A*0201+ Untreated mUM with ctDNA', biomarkerName: 'ctDNA', setting: '1L', tumorType: 'Melanoma', phase: 'Phase 2', cutoffValue: 'HLA-A*0201+ & ctDNA', cutoffUnit: 'HLA + ctDNA', cutoffOperator: 'positive', assayName: 'HLA typing + ctDNA', assayManufacturer: 'Various', companionDiagnostic: true, sponsor: 'Academic', status: 'Recruiting', startYear: 2025 },
  { nctId: 'NCT05136196', trialTitle: 'BiCaZO: Cabozantinib+Nivo Stratified by Tumor Biomarkers (IO-Refractory Melanoma)', biomarkerName: 'TMB', setting: '2L', tumorType: 'Melanoma', phase: 'Phase 2', cutoffValue: 'Tumor biomarker stratified', cutoffUnit: 'composite', cutoffOperator: 'positive', assayName: 'IHC + NGS panel', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'NCI', status: 'Recruiting', startYear: 2022 },

  // ===== HEAD & NECK =====
  { nctId: 'NCT06082167', trialTitle: 'Zanzalintinib+Pembro vs Pembro in PD-L1+ R/M HNSCC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'Head & Neck SCC', phase: 'Phase 2/3', cutoffValue: '1', cutoffUnit: 'CPS', cutoffOperator: '>=', assayName: '22C3 pharmDx', assayManufacturer: 'Dako/Agilent', companionDiagnostic: true, sponsor: 'Exelixis', status: 'Active', startYear: 2024 },

  // ===== ENDOMETRIAL =====
  { nctId: 'NCT04634877', trialTitle: 'KEYNOTE-B21: Pembro Adjuvant in High-Risk Endometrial Cancer', biomarkerName: 'MSI', setting: 'Adjuvant', tumorType: 'Endometrial Cancer', phase: 'Phase 3', cutoffValue: 'dMMR/MSI-H subgroup', cutoffUnit: 'status', cutoffOperator: 'positive', assayName: 'IHC + MSI PCR', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'Merck', status: 'Active', startYear: 2021 },
  { nctId: 'NCT06951504', trialTitle: 'TroFuse-033: Sac-TMT+Pembro Maintenance in pMMR Endometrial Cancer', biomarkerName: 'MSI', setting: 'Maintenance', tumorType: 'Endometrial Cancer', phase: 'Phase 3', cutoffValue: 'pMMR (MSS)', cutoffUnit: 'MMR status', cutoffOperator: 'negative', assayName: 'IHC for MMR', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'Merck', status: 'Recruiting', startYear: 2025 },

  // ===== UROTHELIAL =====
  { nctId: 'NCT03528694', trialTitle: 'POTOMAC: Durvalumab+BCG vs BCG in HR NMIBC', biomarkerName: 'PD-L1', setting: '1L', tumorType: 'Urothelial Carcinoma', phase: 'Phase 3', cutoffValue: 'All-comers (PD-L1 assessed)', cutoffUnit: '% TC/IC', cutoffOperator: '>=', assayName: 'SP263', assayManufacturer: 'Ventana/Roche', companionDiagnostic: false, sponsor: 'AstraZeneca', status: 'Active', startYear: 2018 },

  // ===== HEPATOCELLULAR =====
  { nctId: 'NCT04102098', trialTitle: 'IMbrave050: Atezo+Bev Adjuvant in HCC High Risk of Recurrence', biomarkerName: 'PD-L1', setting: 'Adjuvant', tumorType: 'Hepatocellular Carcinoma', phase: 'Phase 3', cutoffValue: 'All-comers', cutoffUnit: 'PD-L1 assessed', cutoffOperator: '>=', assayName: 'SP263', assayManufacturer: 'Ventana/Roche', companionDiagnostic: false, sponsor: 'Roche', status: 'Active', startYear: 2019 },

  // ===== GASTRIC =====
  { nctId: 'NCT06084755', trialTitle: 'VIKTORY-2: T-DXd+Afatinib in HER2-low Advanced Gastric Cancer', biomarkerName: 'HER2', setting: '2L', tumorType: 'Gastric Cancer', phase: 'Phase 1/2', cutoffValue: 'HER2-low', cutoffUnit: 'IHC 1+ or 2+/ISH-', cutoffOperator: '>=', assayName: 'HercepTest', assayManufacturer: 'Dako/Agilent', companionDiagnostic: false, sponsor: 'Academic (Korea)', status: 'Recruiting', startYear: 2024 },

  // ===== OVARIAN =====
  { nctId: 'NCT03740165', trialTitle: 'KEYLYNK-001: Pembro+Chemo→Olaparib Maintenance in BRCA-WT EOC', biomarkerName: 'BRCA1/2', setting: 'Maintenance', tumorType: 'Ovarian Cancer', phase: 'Phase 3', cutoffValue: 'BRCA non-mutated', cutoffUnit: 'mutation', cutoffOperator: 'negative', assayName: 'BRACAnalysis CDx', assayManufacturer: 'Myriad Genetics', companionDiagnostic: true, sponsor: 'Merck', status: 'Active', startYear: 2018 },

  // ===== TMB PAN-TUMOR =====
  { nctId: 'NCT05770102', trialTitle: 'DETERMINE: Atezolizumab in TMB-H/MSI-H/CMMRD Cancers', biomarkerName: 'TMB', setting: '2L', tumorType: 'NSCLC', phase: 'Phase 2/3', cutoffValue: 'TMB-H or MSI-H', cutoffUnit: 'mut/Mb', cutoffOperator: '>=', assayName: 'Local NGS panel', assayManufacturer: 'Various', companionDiagnostic: false, sponsor: 'Cancer Research UK', status: 'Recruiting', startYear: 2023 },
];

export const LIVE_NEWS: NewsUpdate[] = [
  { id: 'live-1', title: '144 Active Phase 3 PD-L1 Trials — ClinicalTrials.gov Live', source: 'ClinicalTrials', date: '2026-02-10', summary: 'Real-time query identified 144 active/recruiting Phase 3 trials using PD-L1. NSCLC remains dominant, with expanding use in HNSCC, endometrial, and TNBC. Ivonescimab and sigvotatug vedotin are challenging pembrolizumab monotherapy in PD-L1 high NSCLC.', url: 'https://clinicaltrials.gov', biomarkers: ['PD-L1'], tags: ['Live Data', 'Phase 3', 'Pan-Tumor'] },
  { id: 'live-2', title: 'KRAS G12C Combinations Accelerate — 3 New Phase 3 Trials in 2025', source: 'ClinicalTrials', date: '2026-02-10', summary: 'Three major Phase 3 trials launched in 2025 for KRAS G12C NSCLC: SUNRAY-02 (Lilly olomorasib+IO), KRYSTAL-4 (Mirati adagrasib+pembro+chemo), and KANDLELIT-007 (Merck MK-1084+SC pembro). 1L combination is now the primary battleground.', url: 'https://clinicaltrials.gov', biomarkers: ['KRAS'], tags: ['Live Data', 'Phase 3', '1L Combinations'] },
  { id: 'live-3', title: '36 Active HER2-Low/Ultralow Trials — T-DXd Expanding Rapidly', source: 'ClinicalTrials', date: '2026-02-10', summary: 'ClinicalTrials.gov shows 36 trials for HER2-low and ultralow. DESTINY-Lung06 (Phase 3, 1L NSCLC) and ERADICATE (elacestrant+T-DXd in HER2-ultralow BC) highlight the expansion beyond breast cancer into a pan-tumor HER2-directed ADC strategy.', url: 'https://clinicaltrials.gov', biomarkers: ['HER2'], tags: ['Live Data', 'HER2-ultralow', 'ADC'] },
  { id: 'live-4', title: 'ctDNA/MRD-Guided Paradigm Shift — 12 Recruiting Trials', source: 'ClinicalTrials', date: '2026-02-10', summary: '12 recruiting ctDNA/MRD-guided trials across CRC (Phase 3 intensification), NSCLC (de-escalation/escalation), and breast cancer. Signatera (Natera) and Guardant platforms dominate. The ctDNA response-adaptive NSCLC trial (CCTG) is pioneering a new paradigm.', url: 'https://clinicaltrials.gov', biomarkers: ['ctDNA'], tags: ['Live Data', 'MRD', 'Adjuvant'] },
  { id: 'live-5', title: 'Dual Biomarker Strategies Emerge: PD-L1+CD73, KRAS+PD-L1 TPS', source: 'ClinicalTrials', date: '2026-02-10', summary: 'Multiple new trials require dual biomarker selection: KANDLELIT-004 selects KRAS G12C AND PD-L1 TPS≥50%; TJ Biopharma selects PD-L1+ AND CD73+. Combinatorial biomarker strategies are replacing single-biomarker enrichment.', url: 'https://clinicaltrials.gov', biomarkers: ['PD-L1', 'KRAS'], tags: ['Live Data', 'Dual Biomarker', 'Precision Medicine'] },
  { id: 'live-6', title: 'LUNG-MAP Continues to Enroll 10,000+ Patients — Largest Biomarker Platform Trial', source: 'ClinicalTrials', date: '2026-02-10', summary: 'SWOG LUNG-MAP (NCT03851445) remains the largest biomarker-driven platform trial with 10,000 patient enrollment target across 1,201 sites. Using FoundationOne CDx for molecular profiling, it continues to evaluate novel therapies in biomarker-selected NSCLC subpopulations.', url: 'https://clinicaltrials.gov', biomarkers: ['TMB', 'PD-L1', 'EGFR', 'ALK'], tags: ['Live Data', 'Platform Trial', 'NSCLC'] },
];
